Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
A phase 2 trial of Tusamitamab ravtansine and Gemcitabine in Breast cancer, run by Sanofi, recorded as terminated on the registry.
Overview
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors is a phase 2 interventional study registered as NCT04659603 by Sanofi, with 50 participants recorded, started 2021-03-29 and due to reach its primary completion in 2024-02-16. Interventions recorded: tusamitamab ravtansine, Gemcitabine. Conditions recorded: Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic.
Linked to the drug Tusamitamab ravtansine because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialSAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Shares Tusamitamab ravtansine, Sanofi and the tag pipeline.
- TrialA Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
Shares Sanofi, Breast cancer (all types), Gemcitabine and the tag pipeline.
- TrialStudy of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
Shares Sanofi, Breast cancer (all types), Gemcitabine and the tag pipeline.
- TrialTusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Shares Tusamitamab ravtansine, Sanofi and the tag pipeline.
- TrialTwo Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
Shares Sanofi, Breast cancer (all types) and the tag pipeline.
- TrialRC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
Shares Breast cancer (all types), Gemcitabine and the tag pipeline.
- TrialMobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
Shares Sanofi and the tag pipeline.
- TrialImplementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Shares Breast cancer (all types) and the tag pipeline.